SCHEMBL6980492

SCHEMBL6980492

CN(C)c1ccc(-n2c(=O)[nH]c3ccccc3c2=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.58
GAA P10253 2/20 0.56
NPC1 O15118 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
KDM4E B2RXH2 3/20 0.56
NPEPPS P55786 2/20 0.52
ADORA3 P0DMS8 1/20 0.51
ADORA2A P29274 1/20 0.51
ADORA2B P29275 1/20 0.51
ADORA1 P30542 1/20 0.51
HTT P42858 2/20 0.50
PDE7A Q13946 1/20 0.50
PDE7B Q9NP56 1/20 0.50
CYP1A2 P05177 1/20 0.48
ALDH1A1 P00352 3/20 0.47
CA12 O43570 1/20 0.47
RNASEH1 O60930 1/20 0.47
ERCC1 P07992 1/20 0.47
ERCC5 P28715 1/20 0.47
FEN1 P39748 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6976604 0.85 KDM4E (0.67) TP53GAANPC1SMN1; SMN2KDM4E
SCHEMBL6970729 0.83 GAA (0.64) TP53GAANPC1SMN1; SMN2KDM4E
SCHEMBL6981446 0.82 KDM4E (0.71) TP53GAANPC1SMN1; SMN2KDM4E
SCHEMBL6971771 0.81 HTT (0.72) TP53GAANPC1SMN1; SMN2KDM4E
SCHEMBL6973874 0.80 TP53 (0.62) TP53GAANPC1SMN1; SMN2KDM4E
SCHEMBL12889780 0.80 TP53 (0.62) TP53GAANPC1SMN1; SMN2KDM4E
SCHEMBL6977596 0.80 KDM4E (0.73) TP53GAANPC1SMN1; SMN2KDM4E
SCHEMBL1548586 0.80 TP53 (0.62) TP53GAANPC1SMN1; SMN2KDM4E
SCHEMBL6973438 0.79 HSD17B10 (0.66) TP53GAANPC1SMN1; SMN2KDM4E
SCHEMBL8214616 0.78 GAA (0.69) TP53GAANPC1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030199530-A1 New compounds derived from quinazoline LES LABORATORIES SERVIER (FR) 2003-10-23 US disclosed
EP-1346992-A1 Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199530-A1 New compounds derived from quinazoline NQO2, XDH, DRD1 TP53 3198/4885GAA 638/4885NPC1 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.